NCT05544019 Study of SGR-1505 in Mature B-Cell Neoplasms
| NCT ID | NCT05544019 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Schrödinger, Inc. |
| Condition | Mature B-Cell Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 98 participants |
| Start Date | 2023-04-10 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 98 participants in total. It began in 2023-04-10 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Eligibility Criteria
Inclusion Criteria: * Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy. * Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy ≥ 12 weeks. Exclusion Criteria: * The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit). * Subject has previous invasive malignancy in the last 2 years. * Subject has a known allergy to SGR-1505 or excipients of SGR-1505. * Subject has symptomatic or active CNS involvement of disease. * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.
Contact & Investigator
Frank G Basile, M.D.
STUDY DIRECTOR
Schrodinger Inc.
Frequently Asked Questions
Who can join the NCT05544019 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mature B-Cell Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05544019 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05544019 currently recruiting?
Yes, NCT05544019 is actively recruiting participants. Contact the research team at sdgr-trials-group@schrodinger.com for enrollment information.
Where is the NCT05544019 trial being conducted?
This trial is being conducted at Gilbert, United States, Newark, United States, Pompano Beach, United States, Boston, United States and 11 additional locations.
Who is sponsoring the NCT05544019 clinical trial?
NCT05544019 is sponsored by Schrödinger, Inc.. The principal investigator is Frank G Basile, M.D. at Schrodinger Inc.. The trial plans to enroll 98 participants.